AndroGel vs Jatenzo: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

AndroGel and Jatenzo both raise serum testosterone in men with hypogonadism, but they use entirely different absorption mechanisms. AndroGel delivers testosterone through intact skin into subcutaneous tissue and then the bloodstream. Jatenzo relies on dietary fat to form chylomicrons in the small intestine, which carry testosterone undecanoate into the lymphatic system, avoiding first-pass hepatic metabolism entirely.

AndroGel: Transdermal Pharmacokinetics

AndroGel 1.62% (AbbVie) was studied in a 182-subject, open-label, 182-day trial that confirmed dose-proportional increases in serum testosterone [1]. After a single application, testosterone concentrations peak in roughly 2 hours and remain elevated for 24 hours. The gel is applied once daily to the upper arms, shoulders, or abdomen, depending on the formulation. Steady-state concentrations are typically reached within 24 to 48 hours of initiating therapy [1].

Jatenzo: Lymphatic Oral Absorption

Jatenzo's key Phase 3 trial (Swerdloff et al., Journal of Clinical Endocrinology and Metabolism, 2020) enrolled 166 men with primary or secondary hypogonadism [2]. At 16 weeks, 87% of subjects achieved a mean 24-hour testosterone concentration (C-avg) within the normal range of 300 to 1,000 ng/dL on at least one dose level [2]. Because absorption depends on dietary fat, men must take Jatenzo with a meal containing at least 15 grams of fat, skipping or reducing fat intake can cut bioavailability by more than 40% [2].

Efficacy: Normalizing Serum Testosterone

Both drugs achieve testosterone normalization in the majority of treated men, but the clinical trial designs differ enough to make direct comparisons imprecise.

AndroGel Trial Data

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 or older with low testosterone (below 275 ng/dL), used testosterone gel as the active treatment [3]. At 12 months, gel-treated men showed a mean serum testosterone increase from approximately 234 ng/dL to 532 ng/dL [3]. Sexual function scores improved significantly versus placebo (P<0.001), and bone mineral density at the lumbar spine increased by a mean of 3.5% in the bone trial sub-group [3].

Normalization rates in real-world prescribing vary. A 2017 analysis of insurance claims data found that roughly 60 to 65% of men on testosterone gel maintained levels within the 300 to 1,000 ng/dL window after 6 months, with under-dosing being the most common reason for sub-therapeutic levels.

Jatenzo Trial Data

In the Swerdloff et al. Trial, 87% of men achieved normal C-avg on at least one titration step, and 76% maintained normal levels through week 16 at their final dose [2]. Mean testosterone rose from a baseline of 215 ng/dL to 489 ng/dL at steady state [2]. No liver enzyme elevations meeting hepatotoxicity criteria were observed, which directly addresses a historical concern about oral 17-alpha-alkylated androgens, Jatenzo is not 17-alpha-alkylated [2].

The table below summarizes key efficacy metrics from the primary trials.

| Metric | AndroGel (T-Trials) [3] | Jatenzo (Swerdloff 2020) [2] | |---|---|---| | N (efficacy analysis) | 788 | 166 | | Baseline testosterone (ng/dL) | ~234 | ~215 | | On-treatment testosterone (ng/dL) | ~532 | ~489 | | % achieving 300 to 1,000 ng/dL | ~87% (manufacturer trials) | 76 to 87% | | Trial duration | 12 months | 16 weeks | | Placebo-controlled | Yes | No (open-label titration) |

Safety and Adverse Effects

Cardiovascular and Blood Pressure

Blood pressure elevation is Jatenzo's most prominent safety signal. In the Swerdloff et al. Trial, 24% of men experienced a systolic blood pressure increase of 6 mmHg or more from baseline, and 5% met criteria for new hypertension [2]. The FDA added a black-box warning to Jatenzo's label for blood pressure increases that may raise the risk of major adverse cardiovascular events (MACE) [4].

AndroGel carries its own cardiovascular concerns. The FDA issued a Drug Safety Communication in 2014 requiring labeling changes across all testosterone products to reflect possible cardiovascular risk [5]. The signal from the broader TRT literature is mixed. The T-Trials found no significant increase in cardiovascular events in gel-treated men over 12 months, though the study was not powered for MACE [3].

The TRAVERSE trial (N=5,246), completed in 2023, examined testosterone replacement in men aged 45 to 80 with pre-existing or high cardiovascular risk and used testosterone gel as the study drug [6]. Non-inferiority was demonstrated for MACE versus placebo over a median 33-month follow-up, though atrial fibrillation was more common in the testosterone arm (hazard ratio 1.35, 95% CI 1.08 to 1.69) [6].

Skin Transfer Risk

AndroGel carries a black-box warning about secondary testosterone exposure in women and children through skin-to-skin contact [1]. Cases of virilization in female partners and premature puberty in children have been reported post-marketing. Men must wash hands thoroughly after application, allow the gel to dry completely, and cover the application site before contact with others [1].

Jatenzo has no transfer risk. This may make oral dosing preferable for men with young children in the household or for couples where the female partner is of reproductive age.

Hepatotoxicity

The older oral androgen methyltestosterone carries substantial hepatotoxicity risk due to its 17-alpha-alkylation. Jatenzo uses a different chemical structure, testosterone undecanoate, which does not share this liability [2]. Liver function tests in the Swerdloff et al. Trial remained within normal limits throughout the 16-week study period [2].

Erythrocytosis

Both agents can raise hematocrit. Testosterone stimulates erythropoietin production and increases red cell mass. The T-Trials reported a hematocrit rise above 54% in 5.7% of gel-treated men at 12 months [3]. Jatenzo trial data showed similar rates. Monitoring hematocrit every 3 months during the first year of TRT is standard practice per Endocrine Society guidelines [7].

Dosing, Titration, and Monitoring

AndroGel Dosing

AndroGel 1.62% starts at 40.5 mg (2 pump actuations or 2 packets) once daily. If testosterone remains below 300 ng/dL after two weeks, the dose increases to 60.75 mg (3 actuations). The maximum dose is 81 mg (4 actuations) [1]. Serum testosterone should be measured 2 to 8 hours after application to capture peak levels, or at approximately 14 days after any dose change.

Jatenzo Dosing

Jatenzo starts at 237 mg (one 237 mg capsule) twice daily with food. After 3 to 4 weeks, the prescriber measures C-avg or a 4 to 6 hour post-dose level and adjusts: down to 158 mg if testosterone exceeds 1,050 ng/dL, or up to 396 mg (two 198 mg capsules) if testosterone remains below 300 ng/dL [2][4]. Twice-daily dosing with a fat-containing meal is a compliance challenge for some patients.

Monitoring Schedule

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends checking testosterone, hematocrit, and PSA at 3 months after starting TRT, then every 6 to 12 months once levels are stable [7]. The guideline states: "We suggest checking testosterone levels 3 to 6 months after starting treatment to assess whether the patient has achieved mid-normal testosterone levels" [7]. Both AndroGel and Jatenzo fall within this monitoring framework.

Pharmacoeconomics and Access

AndroGel is available as a generic testosterone gel (multiple manufacturers) since 2015, dropping the monthly cost substantially. Cash-pay generic testosterone gel can cost $30 to 80 per month depending on dose and pharmacy. Brand-name AndroGel 1.62% runs $400 to 600 per month without insurance.

Jatenzo has no generic equivalent as of early 2025. Cash-pay cost is approximately $500 to 700 per month. Some commercial insurance plans cover it, but prior authorization is common and often requires documentation of failure or intolerance of at least one other testosterone formulation.

For patients with intact insurance coverage and a clinical reason to prefer oral administration, adherence to injection schedules, needle phobia, or the transfer-risk concerns noted above, Jatenzo may be cost-justified. For most otherwise uncomplicated cases, generic testosterone gel offers equivalent efficacy at a fraction of the price.

Switching from AndroGel to Jatenzo

Men switch from AndroGel to Jatenzo for several reasons: concern about transfer to partners or children, frustration with daily topical application, subtherapeutic levels on gel, or blood pressure that was already well-controlled and where the patient accepts the Jatenzo BP signal.

How to Switch Safely

The switch does not require a washout period. AndroGel's half-life after cessation is roughly 72 hours, so new steady-state Jatenzo levels are established within 3 to 4 weeks of initiating the oral capsules. The prescribing clinician should:

1. Stop AndroGel on the morning of the switch date.
2. Start Jatenzo 237 mg twice daily with the first fat-containing meal of that day.
3. Recheck testosterone (4 to 6 hours post-dose) and blood pressure at 3 to 4 weeks.
4. Titrate dose based on the measured level per the prescribing information [4].

Men with a history of uncontrolled hypertension, stage 2 hypertension, or established MACE risk should have blood pressure optimized before starting Jatenzo and should be monitored at 3 weeks and 3 months post-switch [4].

Who Should Not Switch

Men with systolic blood pressure above 160 mmHg despite antihypertensive therapy, a recent (within 6 months) myocardial infarction or stroke, or class III/IV heart failure are generally not good candidates for Jatenzo given its BP-elevation signal [4]. For these patients, continuing gel, switching to testosterone cypionate or enanthate injections, or using testosterone pellets offers a path to TRT without the cardiovascular uncertainty of the oral formulation.

Patient Profiles: Matching the Drug to the Person

Not every man on TRT has the same priorities. The choice between AndroGel and Jatenzo often comes down to lifestyle and risk factors rather than pure pharmacology.

Prefer AndroGel when:

• Cost is a primary driver and generic gel is accessible.
• The patient is comfortable with daily topical application and lives alone or can reliably cover application sites.
• Cardiovascular risk is elevated (recent MACE, poorly controlled hypertension).
• The patient is already achieving good testosterone levels without skin-transfer issues.

Prefer Jatenzo when:

• Young children or a reproductive-age female partner share the household and transfer risk is a genuine concern.
• The patient has failed to achieve therapeutic levels on two or more dose increases of gel despite confirmed adherence.
• The patient prefers oral administration and can reliably take the capsules with a fat-containing meal twice daily.
• Blood pressure is normal or well-controlled, and the patient understands and accepts the BP-elevation risk.

What the Guidelines Say

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends testosterone therapy for men with symptoms of hypogonadism and consistently low serum testosterone (below 300 ng/dL on two morning measurements) [7]. The guideline does not preferentially recommend one formulation over another for most patients, noting that "the choice of preparation should take into account patient preference, cost, and pharmacokinetic profile" [7].

The American Urological Association's 2018 guideline on testosterone deficiency states that all approved testosterone formulations are acceptable first-line options, with the caveat that providers should counsel patients on formulation-specific risks, including transfer risk for gels and blood pressure risk for Jatenzo [8].

Real-World Adherence and Persistence

Persistence data favor injectable testosterone over both topical and oral formulations at the 12-month mark, largely due to less frequent administration. Among topical users, real-world 12-month persistence rates hover around 50 to 60% in claims-based analyses, with application burden and skin irritation cited as the leading reasons for discontinuation.

Jatenzo's twice-daily, meal-dependent dosing has not yet been captured in large real-world persistence studies as of early 2025, given its 2019 approval date. The meal-dependency requirement could reduce adherence relative to once-daily gel in some populations, while the avoidance of topical application could improve it in others. Clinicians should assess individual lifestyle factors before assuming either formulation will be taken consistently.